Genzyme Invests US$700 M in Alnylam in Sign of Resurgent Interest in RNAi Therapeutics
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 2 (Table of Contents)
Published: 11 Feb-2014
DOI: 10.3833/pdr.v2014.i2.2008 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Sanofi’s Genzyme is to pay US$700 M upfront to gain a 12% equity stake in Alnylam Pharmaceuticals in return for rights to access the RNAi specialist’s entire pipeline of genetic medicines in all territories outside of North America and Western Europe up until 2020...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS